Ajinomoto : Financial Statements for the First Quarter Ended June 30, 2025

About this update from Ajinomoto Co., Inc.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. August 4, 2025 Consolidated Financial Results for the Three Months Ended June 30, 2025 (Under IFRS) Company name Ajinomoto Co., Inc. Stock exchange listing Tokyo Stock Exchange Stock Code 2802 URL https://www.ajinomoto.co.jp/company/ Representative Shigeo Nakamura, Representative Executive Officer & President For inquiries Itoomi Watanabe, Corporate Executive & General Manager, Global Finance Department Telephone +81-3-5250-8111 Scheduled date of starting payment of dividend - Preparation of supplementary materials Yes Results briefing Yes (Yen amounts are rounded down to millions, unless otherwise noted.) Consolidated Financial Results for the Three Months Ended June 30, 2025 Consolidated Operating Results (Percentages indicate year-on-year changes.) Sales Business profit Profit before income taxes Profit Three months ended Million yen % Million yen % Million yen % Million yen % June 30, 2025 364,008 (0.4) 47,236 9.7 48,072 20.7 34,926 30.4 June 30, 2024 365,508 7.7 43,073 0.5 39,825 0.6 26,778 (9.6) Profit attributable to owners of the parent company Total comprehensive income Basic earnings per share Diluted earnings per share Three months ended Million yen % Million yen % Yen Yen June 30, 2025 32,218 34.4 24,664 (65.7) 32.62 32.62 June 30, 2024 23,967 (12.0) 71,940 (18.1) 23.49 23.49 Upon the adoption of IFRS, the Ajinomoto Group has introduced "business profit" as a new profit level that will better enable investors, the Board of Directors, and the Management Committee to grasp the core business results and future outlook of each business while also facilitating continual evaluation of the Group's business portfolio by the Board of Directors and the Management Committee. "Business profit" is defined as sales and share of profit of associates and joint ventures minus cost of sales, selling expenses, research and development expenses, and general and administrative expenses. Business profit does not include other operating income or other operating expenses. With a 2-for-1 stock split of the Company's ordinary shares effective April 1, 2025, basic earnings per share and diluted earnings per share were calculated based on the assumption that the stock split was conducted at the beginning of the previous fiscal year ended March 31, 2025. Consolidated Financial Position Total assets Total equity Equity attributable to owners of the parent company Ownership ratio attributable to owners of the parent company As of Million yen Million yen Million yen % June 30, 2025 1,747,492 768,478 702,123 40.2 March 31, 2025 1,721,131 813,273 746,804 43.4 Consolidated Cash Flows Net cash provided by operating activities Net cash used in investing activities Net cash provided by (used in) financing activities Cash and cash equivalents at end of period Three months ended Million yen Million yen Million yen Million yen June 30, 2025 30,419 (28,983) 34,010 197,921 June 30, 2024 38,111 (14,633) (8,818) 191,267 Cash Dividends Annual dividends per share First quarter-end Second quarter-end Third quarter-end Fiscal year-end Total Yen Yen Yen Yen Yen Fiscal year ended March 31,2025 - 40.00 - 40.00 80.00 Fiscal year ending March 31, 2026 - Fiscal year ending March 31, 2026 (Forecast) 24.00 - 24.00 48.00 Revisions from the last forecast released: None With a 2-for-1 stock split of the Company's ordinary shares effective April 1, 2025, the actual dividend amount before the stock split is stated for the fiscal year ended March 31, 2025. Forecast for the Fiscal Year Ending March 31, 2026 (Percentages indicate year-on-year changes.) Sales Business profit Profit attributable to owners of the parent company Basic earnings per share Full-year Million yen % Million yen % Million yen % Yen 1,618,000 5.7 180,000 13.0 120,000 70.7 123.55 Note: Revisions from the last forecast released: None Notes Changes in significant subsidiaries during the period: None Changes in accounting policies and accounting estimates Changes in accounting policies as required by IFRS: None Other changes in accounting policies: None Changes in accounting estimates: None Number of shares outstanding (ordinary shares) Number of shares outstanding at end of period (including treasury stock) As of June 30, 2025 1,005,637,616 As of March 31, 2025 1,005,637,616 Number of shares in treasury stock at end of period As of June 30, 2025 25,888,558 As of March 31, 2025 11,237,848 Average number of shares during period Three months ended June 30, 2025 987,719,450 Three months ended June 30, 2024 1,020,279,772 With a stock split of the Company's ordinary shares effective April 1, 2025, number of shares outstanding (ordinary shares) was calculated based on the assumption that the stock split was conducted at the beginning of the fiscal year ended March 31, 2025. The number of shares in treasury stock at the end of the period includes the Company's shares held by the director's remuneration BIP trust (As of June 30, 2025: 801,600 shares. As of March 31, 2025: 811,200 shares), which was adopted along with the introduction of stock-based remuneration of executive officers based on the Company's medium-term earnings performance for the directors and others. In addition, these Company's shares are included in the treasury stock which is deducted from the number of shares outstanding at the end of the period when calculating the average number of shares during the period. Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None Appropriate use of forecasts and other notes Disclaimer regarding forward-looking statements and other information Forward-looking statements, such as business forecasts, included in this document are based on management's estimates, assumptions, and projections at the time of release. These statements do not promise nor represent a commitment by the Company to achieve these forecasts. Actual operating results may differ significantly due to various factors. For more information regarding our earnings forecasts, see page 5, " 1. Qualitative Information on the Three-month Consolidated Results, (1) Overview of Operating Results ." Where to obtain supplementary materials Supplementary materials will be posted on the Company's website on Monday, August 4, 2025. Table of contents 1 Qualitative Information on the Three-month Consolidated Results ................................................................... 5 (1) Overview of Operating Results .................................................................................................................. 5 (2) Overview of Financial Position ................................................................................................................... 8 (3) Overview of Cash Flows ............................................................................................................................ 8 (4) Analysis of Capital Resources and Liquidity .............................................................................................. 8 2 Condensed Consolidated Financial Statements and Notes............................................................................... 9 (1) Condensed Consolidated Statements of Financial Position ...................................................................... 9 (2) Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Comprehensive Income ............................................................................................................................. 11 (3) Condensed Consolidated Statements of Cash Flows ............................................................................... 13 (4) Notes to Condensed Consolidated Financial Statements ......................................................................... 15 Going Concern Assumption ....................................................................................................................... 15 Significant Changes in Equity Attributable to Owner of the Parent Company 15 Segment Information.................................................................................................................................. 16 Significant Subsequent Events .................................................................................................................. 18 Qualitative Information on the Three-month Consolidated Results Upon the adoption of IFRS, the Ajinomoto Group has introduced "business profit" as a new profit level that will better enable investors, the Board of Directors, and the Management Committee to grasp the core business results and future outlook of each business while also facilitating continual evaluation of the Group's business portfolio by the Board of Directors and the Management Committee. "Business profit" is defined as sales and share of profit of associates and joint ventures minus cost of sales, selling expenses, research and development expenses, and general and administrative expenses. Business profit does not include other operating income or other operating expenses. Overview of Operating Results In the three months ended June 30, 2025, the Company's consolidated sales decreased 0.4% year on year, or ¥1.5 billion, to ¥364.0 billion. This was mainly due to the effect of currency translation, despite increase in sales in the Healthcare and Others segment and other factors. Business profit increased 9.7% year on year, or ¥4.1 billion, to ¥47.2 billion primarily due to the effect of higher revenue in the Healthcare and Others segment. Profit attributable to owners of the parent company totaled ¥32.2 billion, up 34.4% year on year, or ¥8.2 billion, primarily due to the realization of exchange differences on translation of foreign operations resulting from the sale of Ajinomoto Althea, Inc. The Company has not revised the financial results forecast announced on May 8, 2025. Overview by segment Sales and business profit by segment are summarized below. Versus previous year results (Billions of yen) Sales Business Profit FY2025 Q1 YoY change % change FY2025 Q1 YoY change % change Seasonings and Foods 213.3 (0.9) (0.5)% 36.3 1.2 3.6% Frozen Foods 68.7 (1.4) (2.0)% 2.8 (1.1) (28.4)% Healthcare and Others 78.9 0.8 1.1% 15.4 3.8 33.8% Other 2.8 0.0 2.4% 1.9 0.0 0.2% Shared companywide expenses* - - - (9.2) 0.1 (1.3)% Total 364.0 (1.5) (0.4)% 47.2 4.1 9.7% Versus the forecast (Billions of yen) Sales Business Profit FY2025 Q1 Forecast for the year YTD progress FY2025 Q1 Forecast for the year YTD progress Seasonings and Foods 213.3 959.2 22.2% 36.3 139.1 26.1% Frozen Foods 68.7 304.0 22.6% 2.8 15.0 18.7% Healthcare and Others 78.9 339.0 23.3% 15.4 62.6 24.6% Other 2.8 15.6 18.4% 1.9 6.3 30.1% Shared companywide expenses* - - - (9.2) (43.2) 21.4% Total 364.0 1,618.0 22.5% 47.2 180.0 26.2% *Shared companywide expenses are expenses not attributable to specific reportable segments and used to be allocated to each reportable segment based on certain criteria according to the management approach. However, in order to more appropriately evaluate the performance of each reportable segment, the Company has decided not to allocate shared companywide expenses to reportable segments beginning this current fiscal year. This change has been applied retroactively to the segment figures for the previous fiscal year. As a result of this change, in the first quarter of the previous fiscal year, segment business profit increased ¥4.6 billion in Seasonings and Foods, ¥1.0 billion in Frozen Foods, ¥3.4 billion in Healthcare and Others, and ¥0.1 billion in Other, while shared companywide expenses decreased ¥9.3 billion. Shared companywide expenses mainly relate to the parent company's administrative divisions. Seasonings and Foods Main factors affecting segment sales Sauce & Seasonings: Overall revenue was level with the previous year. Japan: Increase in revenue primarily due to the effect of increased unit sales prices. Overseas: Decrease in revenue due to the impact of currency translation, despite increased sales. Quick Nourishment: Overall increase in revenue. Japan: Increase in revenue primarily due to the effect of increased unit sales prices. Overseas: Despite the effect of increased unit sales prices, revenue was leve with the previous year due to a decline in sales volume. Solution & Ingredients: Decrease in revenue due to decreased sales and the impact of currency translation. Main factors affecting segment profits Sauce & Seasonings: Overall increase in profit. Japan: Decrease in profit primarily due to cost increase for raw materials, despite increase in revenue. Overseas: Increase in profit primarily due to increased sales and improved product mix, despite the impact of currency translation. Quick Nourishment: Overall large increase in profit. Japan: Increase in profit primarily due to the effect of increased revenue. Overseas: Increase in profit primarily due to the effect of increased unit sales prices. Solution & Ingredients: Overall decrease in profit accompanying decrease in revenue. In the Seasonings and Foods segment, sales decreased 0.5% year on year, or ¥0.9 billion, to ¥213.3 billion, mainly because of the effect of currency translation. Segment business profit increased 3.6% year on year, or ¥1.2 billion, to ¥36.3 billion, due primarily to the impact of higher unit prices, despite the effect of currency translation. l Frozen Foods Frozen Foods segment sales decreased 2.0% year on year, or ¥1.4 billion, to ¥68.7 billion, primarily owing to the effect of currency translation. Segment business profit decreased 28.4% year on year, or ¥1.1 billion, to ¥2.8 billion, mainly because of lower revenue among other factors. Main factors affecting segment sales Overall decrease in revenue. Japan: Overall decrease in revenue due to decreased sales of home-use products. Overseas: Decrease in revenue due to the impact of currency translation, despite increased sales. Main factors affecting segment profits Overall large decrease in profit. Japan: Decrease in profit accompanying decrease in revenue. Overseas: Decrease in profit primarily due to increased strategic expenses and the impact of currency translation. Healthcare and Others Main factors affecting segment sales Bio-Pharma Services & Ingredients: Overall increase in revenue due to increased sales of amino acids for pharmaceuticals and foods and Bio-Phar Services (CDMO services), despite the impacts of selling Ajinomoto Althea, Inc. and of currency translation. Functional Materials (electronic materials and others): Large increase in revenue due to strong sales of electronic materials. Others: Overall large decrease in revenue. Main factors affecting segment profits Bio-Pharma Services & Ingredients: Overall large increase in profit primarily due to the effect of increased revenue from both amino acids for pharmaceuticals and foods and Bio-Pharma Services (CDMO services). Functional Materials (electronic materials and others): Large increase in profit accompanying large increase in revenue. Others: Overall large decrease in profit primarily due to strategic expenses. Healthcare and Others segment sales increased 1.1% year on year, or ¥0.8 billion, to ¥78.9 billion, owing to strong sales of electronic materials and other factors. Segment business profit increased 33.8% year on year, or ¥3.8 billion, to ¥15.4 billion mainly due to an increase in profit for Bio-Pharma Services & Ingredients and the effect of higher revenue for electronic materials. ma Other In the Other segment, sales increased 2.4% year on year to ¥2.8 billion. Segment business profit totaled ¥1.9 billion, up 0.2%, year on year. Overview of Financial Position As of June 30, 2025, the Company's consolidated total assets stood at ¥1,747.4 billion, an increase of ¥26.3 billion from ¥1,721.1 billion at the end of the previous fiscal year on March 31, 2025. The main reasons for this were increases in cash and cash equivalents and inventories. Total liabilities came to ¥979.0 billion, ¥71.1 billion more than the ¥907.8 billion at the end of the previous fiscal year, mainly due to an increase in interest bearing debt. Interest bearing debt totaled ¥598.7 billion, an increase of ¥102.6 billion from the end of the previous fiscal year, mainly due to the issuance of commercial papers. Total equity as of June 30, 2025 was ¥44.7 billion less than at the end of the previous fiscal year, mainly due to purchase of treasury stock. Equity attributable to owners of the parent company, which is total equity minus non-controlling interests, totaled ¥702.1 billion, and the equity ratio attributable to owners of the parent company was 40.2%. Overview of Cash Flows The overview of cash flows for the three months ended June 30, 2025 is as follows: Net cash provided by operating activities totaled ¥30.4 billion during the three months ended June 30, 2025, compared with ¥38.1 billion during the three months ended June 30, 2024. The main factors included ¥48.0 billion in profit before income taxes and ¥21.0 billion in depreciation and amortization, offset by a ¥18.4 billion increase in inventories, and ¥10.4 billion in income taxes paid. Net cash used in investing activities came to ¥28.9 billion during the three months ended June 30, 2025, compared with ¥14.6 billion during the three months ended June 30, 2024. The main factors included ¥30.3 billion in purchase of property, plant and equipment, and intangible assets. Net cash provided by financing activities was ¥34.0 billion during the three months ended June 30, 2025, compared with net cash used in financing activities of ¥8.8 billion during the three months ended June 30, 2024. The main factors included ¥110.0 billion in net proceeds from issuance of commercial papers, which offset ¥46.6 billion in purchase of treasury stock, ¥18.8 billion in dividends paid, and ¥7.8 billion in repayments of long-term borrowings. As a result of the foregoing, cash and cash equivalents as of June 30, 2025 totaled ¥197.9 billion. Analysis of Capital Resources and Liquidity Liquidity During the three months ended June 30, 2025, the Company ensured adequate short-term liquidity on hand through funding methods that mainly consisted of committed credit lines, overdraft facilities, and commercial paper issuance facilities. Moreover, in addition to maintaining an adequate ratio of liquidity on hand, the Company ensured funding security through committed credit lines concluded with its main banks. As of June 30, 2025, the unused amount of committed credit lines was ¥190.0 billion in Japanese yen and US$100 million in foreign currency. Furthermore, the Company provides an emergency loan facility to respond to temporary cash shortages at overseas consolidated subsidiaries with a high possibility of liquidity risks. Fund Procurement In the three months ended June 30, 2025, the Company raised funds mainly through the issuance of commercial papers in order to fund its operations, taking into consideration the balance between direct and indirect finance from the perspective of funding costs and risk diversification, and the balance between longterm and short-term funding. Use of Funds During the three months ended June 30, 2025, funds were primarily used to finance business operations. 2. Condensed Consolidated Financial Statements and Notes (1) Condensed Consolidated Statements of Financial Position (Millions of yen) As of June 30, 2025 As of March 31, 2025 Assets Current assets Cash and cash equivalents 197,921 164,776 Trade and other receivables 175,194 174,136 Other financial assets 15,008 17,990 Inventories 305,329 286,952 Income taxes receivable 13,928 12,533 Others 24,765 27,600 Subtotal 732,148 683,989 Assets of disposal groups classified as held for sale - 17,308 Total current assets 732,148 701,298 Non-current assets Property, plant and equipment 574,747 581,330 Intangible assets 89,692 92,168 Goodwill 115,698 117,940 Investments in associates and joint ventures 129,554 129,645 Long-term financial assets 50,738 45,823 Deferred tax assets 9,045 10,198 Others 45,866 42,727 Total non-current assets 1,015,343 1,019,833 Total assets 1,747,492 1,721,131 (Millions of yen) As of June 30, 2025 As of March 31, 2025 Liabilities Current liabilities Trade and other payables 228,895 240,614 Short-term borrowings 7,471 5,923 Commercial papers 110,000 - Current portion of bonds 24,992 24,989 Current portion of long-term borrowings 1,691 8,234 Other financial liabilities 9,592 9,637 Short-term employee benefits 40,166 47,217 Provisions 1,695 4,514 Income taxes payable 20,347 19,923 Others 14,673 9,019 Subtotal 459,525 370,075 Liabilities of disposal groups classified as held for sale - 14,512 Total current liabilities 459,525 384,588 Non-current liabilities Corporate bonds 204,434 204,412 Long-term borrowings 209,834 211,795 Other financial liabilities 45,871 46,130 Long-term employee benefits 30,202 30,443 Provisions 3,869 4,267 Deferred tax liabilities 21,420 22,989 Others 3,854 3,230 Total non-current liabilities 519,488 523,270 Total liabilities 979,013 907,858 Equity Common stock 79,863 79,863 Capital surplus 92 - Treasury stock (79,267) (32,668) Retained earnings 603,083 590,517 Other components of equity 98,352 105,838 Other components of equity related to disposal groups classified as held for sale - 3,253 Equity attributable to owners of the parent company 702,123 746,804 Non-controlling interests 66,354 66,468 Total equity 768,478 813,273 Total liabilities and equity 1,747,492 1,721,131 (2) Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Comprehensive Income Condensed Consolidated Statements of Income (Millions of yen) Three months ended June 30, 2025 Three months ended June 30, 2024 Sales 364,008 365,508 Cost of sales (224,999) (232,108) Gross profit 139,008 133,400 Share of profit of associates and joint ventures 3,128 2,319 Selling expenses (48,992) (48,468) Research and development expenses (7,345) (7,537) General and administrative expenses (38,562) (36,639) Business profit 47,236 43,073 Other operating income 5,293 1,418 Other operating expenses (3,149) (3,685) Operating profit 49,380 40,805 Financial income 2,247 2,564 Financial expenses (3,555) (3,545) Profit before income taxes 48,072 39,825 Income taxes (13,145) (13,047) Profit 34,926 26,778 Profit attributable to: Owners of the parent company 32,218 23,967 Non-controlling interests 2,708 2,810 Earnings per share (yen): Basic ¥32.62 ¥23.49 Diluted ¥32.62 ¥23.49 Condensed Consolidated Statements of Comprehensive Incom e (Millions of yen) Three months ended June 30, 2025 Three months ended June 30, 2024 Profit 34,926 26,778 Other comprehensive income (Net of related tax effects) Items that will not be reclassified to profit or loss: Net gain on revaluation of financial assets measured at fair value through other comprehensive income 1,356 284 Remeasurements of defined benefit pension plans 901 655 Share of other comprehensive income of associates and joint ventures 55 111 Items that may be reclassified subsequently to profit or loss: Cash flow hedges (204) 267 Hedge surplus (92) 11 Exchange differences on translation of foreign operations (11,979) 44,664 Share of other comprehensive income (loss) of associates and joint ventures (299) (833) Other comprehensive income (Net of related tax effects) (10,262) 45,161 Comprehensive income 24,664 71,940 Comprehensive income attributable to: Owners of the parent company 21,692 65,691 Non-controlling interests 2,971 6,249 (3) Condensed Consolidated Statements of Cash Flows (Millions of yen) Three months ended June 30, 2025 Three months ended June 30, 2024 Cash flows from operating activities Profit before income taxes 48,072 39,825 Depreciation and amortization 21,031 21,437 Impairment loss and gain on reversal of impairment loss 321 349 Increase (decrease) in employee benefits (7,311) (5,562) Increase (decrease) in provisions (3,260) (2,430) Interest and dividend income (1,916) (2,067) Interest expense 1,801 1,514 Share of profit of associates and joint ventures (3,128) (2,319) Loss on sale and retirement of property, plant and equipment, and intangible assets 816 400 Decrease (increase) in trade and other receivables (395) 8,755 Increase (decrease) in trade and other payables 3,699 (5,452) Decrease (increase) in inventories (18,424) (15,847) Increase (decrease) in other assets and liabilities 5,896 (395) Others (7,877) 2,570 Subtotal 39,325 40,776 Interest and dividends received 3,148 3,125 Interest paid (1,623) (1,027) Income taxes paid (10,431) (4,763) Net cash provided by operating activities 30,419 38,111 Cash flows from investing activities Purchase of property, plant and equipment, and intangible assets (30,393) (22,964) Proceeds from sale of property, plant and equipment, and intangible assets 117 1,252 Purchase of financial assets (3,045) (413) Proceeds from sale of financial assets 3,172 7,790 Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation 1,995 - Others (830) (298) Net cash used in investing activities (28,983) (14,633) (Millions of yen) Three months ended June 30, 2025 Three months ended June 30, 2024 Cash flows from financing activities Net change in short-term borrowings 2,100 (88,803) Net change in commercial papers 110,000 57,000 Proceeds from long-term borrowings - 97,006 Repayments of long-term borrowings (7,835) (7,244) Dividends paid (18,811) (18,519) Dividends paid to non-controlling interests (2,588) (11,292) Purchase of treasury stock (46,619) (34,497) Repayments of lease liabilities (2,255) (2,485) Others 19 17 Net cash provided by (used in) financing activities 34,010 (8,818) Effect of currency rate changes on cash and cash equivalents (2,300) 5,071 Net change in cash and cash equivalents 33,145 19,729 Cash and cash equivalents at beginning of period 164,776 171,537 Cash and cash equivalents at end of period 197,921 191,267 Notes to Condensed Consolidated Financial Statements Going Concern Assumption Not applicable Significant Changes in Equity Attributable to Owner of the Parent Company Not applicable Segment Information Overview of reportable segments The Group's reportable segments are categorized primarily by product lines. There are three reportable segments: Seasonings and Foods, Frozen Foods, and Healthcare and Others. Each reportable segment is a component of the Group for which separate financial information is available and evaluated regularly by the Management Committee in determining the allocation of management resources and in assessing performance. Shared companywide expenses are expenses not attributable to specific reportable segments and used to be allocated to each reportable segment based on certain criteria according to the management approach. However, in order to more appropriately evaluate the performance of each reportable segment, the Company has decided not to allocate shared companywide expenses to reportable segments beginning this current fiscal year. This change has been applied retroactively to the segment figures for the previous fiscal year. As a result of this change, in the three months ended June 30, 2024, segment business profit increased ¥4,638 million in Seasonings and Foods, ¥1,056 million in Frozen Foods, ¥3,482 million in Healthcare and Others, and ¥187 million in Other, while shared companywide expenses decreased ¥9,365 million. Shared companywide expenses mainly relate to the parent company's administrative divisions. The product categories belonging to each reportable segment are as follows: Reportable Segments Details Main Products Seasonings and Foods Sauce and Seasonings Umami seasoning AJI-NO-MOTO ® , HON-DASHI ® , Cook Do ® , Ajinomoto KK Consommé , Pure Select ® Mayonnaise , Ros Dee ® (flavor seasoning), Masako ® (flavor seasoning), Aji-ngon ® (flavor seasoning), Sazón ® (flavor seasoning), Sajiku ® (menu-specific seasoning), CRISPY FRY ® (menu-specific seasoning), etc. Quick Nourishment Knorr ® Cup Soup , Yum-Yum ® (instant noodles), Birdy ® (coffee beverage), Birdy ® 3in1 (powdered drink), Blendy ® brand products ( CAFÉ LATORY ® , stick coffee, etc.), MAXIM ® brand products, Chotto Zeitakuna Kohiten ® brand products, various gift sets, office supplies (coffee vending machines, tea servers), etc. Solution and Ingredients Umami seasoning AJI-NO-MOTO ® for foodservice and processed food manufacturers in Japan, Seasonings and processed foods for foodservice, Seasonings for processed foods (savory seasonings, enzyme ACTIVA ® ), Delicatessen products, Bakery products, Nucleotides, Sweeteners (aspartame for industrial use, etc.), and others Frozen Foods Frozen Foods Chinese dumplings ( Gyoza, POT STICKERS , etc.), Cooked rice ( THE CHA-HAN , CHICKEN FRIED RICE , etc.), Noodles ( YAKISOBA , RAMEN , etc.), Sweets (cakes for restaurant and industrial-use, MACARON , etc.), Shumai ( THE SHUMAI , Ebi shumai (shrimp dumpling) , etc.), Processed chicken ( Yawaraka Wakadori Kara-Age (fried chicken), THE KARAAGE , etc.), and others Healthcare and Others Amino Acids for Pharmaceuticals and Foods Amino acids, culture media Bio-Pharma Services (CDMO services) Contract development and manufacturing services of pharmaceutical intermediates and active ingredients and others Functional Materials (electronic materials and others) Electronic materials ( Ajinomoto Build-up Film ® (ABF) interlayer insulating material for semiconductor packages, etc.), Functional materials (adhesive PLENSET ® , magnetic materials AFTINNOVA ® Magnetic Film , etc.), activated carbon, release paper, etc. Others Feed-use amino acids, Sports nutrition (Supplement ( amino VITAL ® ), etc.), Personal care ingredients (an amino acid-based surfactant ( Amisoft ® ), and amino acid-based oil and powder for use in makeup ( Eldew ® and Amihope ® , respectively), etc.), Medical foods, Crop services, etc. Sales and profits by segment The Group's sales and profits by reportable segment are as follows: Inter-segment sales and transfers are primarily based on transaction prices with third parties. Three months ended June 30, 2025 (April 1, 2025 to June 30, 2025) (Millions of yen) Reportable segment Other 1 Total Adjustments 2 As included in consolidated statements of income Seasonings and Foods Frozen Foods Healthcare and Others Sales Sales to third parties 213,387 68,752 78,989 2,878 364,008 - 364,008 Inter-segment sales and transfers 2,097 126 1,434 6,759 10,418 (10,418) - Total sales 215,485 68,879 80,424 9,637 374,427 (10,418) 364,008 Share of profit of associates and joint ventures 1,161 - (35) 2,002 3,128 - 3,128 Segment profit or loss (Business profit or loss) 36,332 2,812 15,412 1,926 56,484 (9,247) 47,236 Other operating income 5,293 Other operating expense (3,149) Operating profit 49,380 Financial income 2,247 Financial expense (3,555) Profit before income taxes 48,072 Other includes the tie-up and other service-related businesses. Adjustments of segment profit or loss are shared companywide expenses, which are expenses not attributable to specific reportable segments. Shared companywide expenses mainly relate to the parent company's administrative divisions. Three months ended June 30, 2024 (April 1, 2024 to June 30, 2024) (Millions of yen) Reportable segment Other 1 Total Adjustments 2 As included in consolidated statements of income Seasonings and Foods Frozen Foods Healthcare and Others Sales Sales to third parties 214,383 70,164 78,149 2,811 365,508 - 365,508 Inter-segment sales and transfers 1,886 89 1,294 9,054 12,324 (12,324) - Total sales 216,270 70,254 79,443 11,865 377,833 (12,324) 365,508 Share of profit of associates and joint ventures 283 - 36 1,998 2,319 - 2,319 Segment profit or loss (Business profit or loss) 35,067 3,928 11,519 1,923 52,438 (9,365) 43,073 Other operating income 1,418 Other operating expense (3,685) Operating profit 40,805 Financial income 2,564 Financial expense (3,545) Profit before income taxes 39,825 Other includes the tie-up and other service-related businesses. Adjustments of segment profit or loss are shared companywide expenses, which are expenses not attributable to specific reportable segments. Shared companywide expenses mainly relate to the parent company's administrative divisions. Significant Subsequent Events Not applicable

View stock analysis, news, and events for Ajinomoto Co., Inc.